The aim was to assess 3-year longitudinal data using 6MWT in 26 ambulant boys affected by DMD carrying nonsense mutations and to compare their results to other small mutations. We also wished to establish, within the nonsense mutations group, patterns of change according to several variables. Patients with nonsense mutations were categorized according to the stop codon type newly created by the mutation and also including the adjacent 5′ (upstream) and 3′ (downstream) nucleotides. No significant difference was found between nonsense mutations and other small mutations (p > 0.05) on the 6MWT. Within the nonsense mutations group, there was no difference in 6MWT when the patients were subdivided according to: Type of stop codon, frame statu...
The molecular basis of two allelic forms of muscular dystrophy, Duchenne (DMD) and Becker (BMD), has...
<div><p>Recent advances in molecular therapies for Duchenne muscular dystrophy (DMD) require precise...
Objective In the last few years some of the therapeutical approaches for Duchenne muscular dystro...
The aim was to assess 3-year longitudinal data using 6MWT in 26 ambulant boys affected by DMD carryi...
A nonsense mutation adds a premature stop signal that hinders any further translation of a protein-c...
A nonsense mutation adds a premature stop signal that hinders any further translation of a protein-c...
A nonsense mutation adds a premature stop signal that hinders any further translation of a protein-c...
Objective:To correlate time to loss of ambulation (LoA) and different truncating DMD gene mutations ...
International audienceStraightforward detectable Duchenne muscular dystrophy (DMD) gene rearrangemen...
In the last few years some of the therapeutical approaches for Duchenne muscular dystrophy (DMD) are...
Antisense oligonucleotide (AON)-mediated exon skipping is an emerging therapeutic for individuals wi...
<div><p>Background</p><p>Approximately 13% of boys with Duchenne muscular dystrophy (DMD) have a non...
Approximately 13% of boys with Duchenne muscular dystrophy (DMD) have a nonsense mutation in the dys...
Background: Approximately 13 % of boys with Duchenne muscular dystrophy (DMD) have a nonsense mutati...
Introduction/Aims Mutations amenable to skipping of specific exons have been associated with differe...
The molecular basis of two allelic forms of muscular dystrophy, Duchenne (DMD) and Becker (BMD), has...
<div><p>Recent advances in molecular therapies for Duchenne muscular dystrophy (DMD) require precise...
Objective In the last few years some of the therapeutical approaches for Duchenne muscular dystro...
The aim was to assess 3-year longitudinal data using 6MWT in 26 ambulant boys affected by DMD carryi...
A nonsense mutation adds a premature stop signal that hinders any further translation of a protein-c...
A nonsense mutation adds a premature stop signal that hinders any further translation of a protein-c...
A nonsense mutation adds a premature stop signal that hinders any further translation of a protein-c...
Objective:To correlate time to loss of ambulation (LoA) and different truncating DMD gene mutations ...
International audienceStraightforward detectable Duchenne muscular dystrophy (DMD) gene rearrangemen...
In the last few years some of the therapeutical approaches for Duchenne muscular dystrophy (DMD) are...
Antisense oligonucleotide (AON)-mediated exon skipping is an emerging therapeutic for individuals wi...
<div><p>Background</p><p>Approximately 13% of boys with Duchenne muscular dystrophy (DMD) have a non...
Approximately 13% of boys with Duchenne muscular dystrophy (DMD) have a nonsense mutation in the dys...
Background: Approximately 13 % of boys with Duchenne muscular dystrophy (DMD) have a nonsense mutati...
Introduction/Aims Mutations amenable to skipping of specific exons have been associated with differe...
The molecular basis of two allelic forms of muscular dystrophy, Duchenne (DMD) and Becker (BMD), has...
<div><p>Recent advances in molecular therapies for Duchenne muscular dystrophy (DMD) require precise...
Objective In the last few years some of the therapeutical approaches for Duchenne muscular dystro...